Form 4: Castle Biosciences Executive Sells Shares Under 10b5-1 Plan

A Castle Biosciences executive, Tobin W. Juvenal, sold 2,230 shares of common stock at $30 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Tobin W. Juvenal, Chief Commercial Officer of Castle Biosciences, sold 2,230 shares of common stock on January 6, 2025.
• The sale was executed at a price of $30 per share.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 11, 2024.
• Following the transaction, Mr. Juvenal directly owns 69,943 shares of Castle Biosciences common stock.
• Additionally, Mr. Juvenal indirectly owns 2,230 shares through the Tobin W and Susan M Juvenal Family Revocable Trust.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an executive's stock sale under a pre-arranged plan. It does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives to use 10b5-1 plans to sell shares to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among corporate executives to manage their stock sales and avoid potential insider trading issues.
• Similar filings are regularly seen across various companies when executives sell shares, especially those with pre-arranged trading plans.
• The volume of shares sold and the price are specific to this executive and company, and would need to be compared to other similar transactions to determine if they are within the expected range.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on shareholder sentiment, but is unlikely to have a significant impact due to the pre-arranged nature of the sale.

Key Dates

Keywords

Castle Biosciences, insider trading, Form 4, 10b5-1 plan, stock sale, CSTL, executive